Mucormycosis of Maxillofacial Region Secondary to COVID-19 Infection and It’s Management: A Review
Dalvi Tanushri *
Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, India.
Shrivardhan Kalghatgi
Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, India.
Asawari Yadav
Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, India.
Pranjali Narale
Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, India.
Prachi Sakpal
Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, India.
*Author to whom correspondence should be addressed.
Abstract
Mucormycosis mainly affects people who have health problems or take medicines that lower the body’s ability to fight germs and sickness. It most commonly affects the sinuses or the lungs after inhaling fungal spores from the air. It can also occur on the skin after a cut, burn, or other type of skin injury. The most common types that cause mucormycosis are Rhizopus species and Mucor species. Mucormycosis is a rare fungal infection with high morbidity and mortality but nowadays it is observed in many covid -19 patients therefore it is identified as a complication after covid-19. It is most commonly seen in patients with systemic illness such as Diabetes Mellitus, Neutropenia, corticosteroid use, Organ transplantation, advanced age and also seen in patients who have stayed prolonged in ICU. This review article includes etiology, risk factors, site specificity, oral manifestations of Mucormycosis, diagnosis based on oral and maxillofacial symptoms and also management of the complications.
Keywords: Dentistry, COVID-19, diabetes mellitus, mucormycosis, necrosis